Tuesday, 5 March 2013
AstraZeneca today announced that the Federal Court of Australia has found three patents protecting CRESTOR (rosuvastatin) to be invalid. These patents – a formulation patent (AU 200051842, with an expiry date in 2020); a second related to the use of rosuvastatin for treating heterozygous familial hypercholesterolemia (AU 2002214165, with an expiry date in 2021); and a third related to the use of rosuvastatin for treating hypercholesterolemia (AU 2000023051, with an expiry date in 2020) – were challenged by Apotex Pty Ltd, Watson Pharma Pty Ltd and Ascent Pharma Pty Ltd.
The Federal Court decision is limited to Australia and has no impact on the validity of patents related to CRESTOR in other countries nor does it have any impact on AstraZeneca’s financial guidance for 2013, which will, in accordance with normal practice, be reviewed in conjunction with the announcement of First Quarter Financial Results on 25 April 2013.
Total sales of CRESTOR in Australia for 2012 were approximately $350 million.
AstraZeneca is disappointed in the court’s decision to find these patents invalid. The company remains committed to defending its intellectual property protecting CRESTOR in Australia and is carefully reviewing this decision and evaluating all legal options at this time, which could include filing an appeal and seeking to maintain existing preliminary injunctions.
NOTES FOR EDITORS
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries | ||
---|---|---|
Media EnquiriesEsra Erkal-Paler | (UK/Global) | +44 20 7604 8030 |
Media EnquiriesVanessa Rhodes |
(UK/Global) | +44 20 7604 8037 |
Media EnquiriesAyesha Bharmal | (UK/Global) |
+44 20 7604 8034 |
Media EnquiriesZoe Tanner |
(Australia) | +61 2 9856 8390 |
Investor Enquiries | ||
---|---|---|
Investor Enquiries James Ward-Lilley | +44 20 7604 8122 | mob: +44 7785 432613 |
Investor Enquiries Karl Hård | +44 20 7604 8123 | mob: +44 7789 654364 |
Investor Enquiries Nicklas Westerholm |
+44 20 7604 8124 | mob: +44 7585 404950 |
Investor Enquiries Ed Seage | +1 302 886 4065 | mob: +1 302 373 1361 |
Investor Enquiries Colleen Proctor | +1 302 886 1842 | mob: +1 302 357 4882 |